MX2019008063A - 17a, 21-diesteres de cortexolona para uso en el tratamiento de tumores. - Google Patents

17a, 21-diesteres de cortexolona para uso en el tratamiento de tumores.

Info

Publication number
MX2019008063A
MX2019008063A MX2019008063A MX2019008063A MX2019008063A MX 2019008063 A MX2019008063 A MX 2019008063A MX 2019008063 A MX2019008063 A MX 2019008063A MX 2019008063 A MX2019008063 A MX 2019008063A MX 2019008063 A MX2019008063 A MX 2019008063A
Authority
MX
Mexico
Prior art keywords
cortexolone
formula
pharmaceutical compositions
active ingredients
treatment
Prior art date
Application number
MX2019008063A
Other languages
English (en)
Inventor
Gerloni Mara
Original Assignee
Cosmo Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cosmo Technologies Ltd filed Critical Cosmo Technologies Ltd
Publication of MX2019008063A publication Critical patent/MX2019008063A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención proporciona ciertos derivados de cortexolona de la formula (I), y la misma para uso como ingredientes activos antitumorales para el tratamiento curativo o adyuvante, o neoadyuvante o paliativo de lesiones precancerosas, displasias, metaplasias y enfermedades tumorales, que incluyen metástasis y neoplasias malignas. Otro aspecto de la invención se refiere a composiciones farmacéuticas que comprenden derivados de cortexolona de la fórmula (I) como ingredientes activos y con al menos un excipiente fisiológicamente aceptable, y para uso de dichas composiciones farmacéuticas como productos médicos antitumorales.
MX2019008063A 2014-10-08 2017-04-07 17a, 21-diesteres de cortexolona para uso en el tratamiento de tumores. MX2019008063A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14188063.3A EP3006453A1 (en) 2014-10-08 2014-10-08 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors

Publications (1)

Publication Number Publication Date
MX2019008063A true MX2019008063A (es) 2019-09-11

Family

ID=51687868

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017004661A MX2017004661A (es) 2014-10-08 2015-10-07 17alfa-benzoato de cortexolona para uso en el tratamiento de tumores.
MX2017004660A MX366294B (es) 2014-10-08 2015-10-07 17a, 21-diesteres de cortexolona para uso en el tratamiento de tumores.
MX2019008063A MX2019008063A (es) 2014-10-08 2017-04-07 17a, 21-diesteres de cortexolona para uso en el tratamiento de tumores.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2017004661A MX2017004661A (es) 2014-10-08 2015-10-07 17alfa-benzoato de cortexolona para uso en el tratamiento de tumores.
MX2017004660A MX366294B (es) 2014-10-08 2015-10-07 17a, 21-diesteres de cortexolona para uso en el tratamiento de tumores.

Country Status (23)

Country Link
US (7) US10231980B2 (es)
EP (4) EP3006453A1 (es)
JP (5) JP6503057B2 (es)
KR (4) KR102248983B1 (es)
CN (5) CN111285913B (es)
AU (3) AU2015329999B2 (es)
BR (2) BR112017007076B1 (es)
CA (3) CA2962746A1 (es)
DK (2) DK3204400T3 (es)
ES (3) ES2882223T3 (es)
HR (2) HRP20190194T1 (es)
HU (2) HUE055143T2 (es)
IL (3) IL272095B2 (es)
LT (2) LT3456330T (es)
MX (3) MX2017004661A (es)
PL (2) PL3204400T3 (es)
PT (2) PT3204400T (es)
RS (2) RS62147B1 (es)
RU (3) RU2712752C2 (es)
SI (2) SI3204400T1 (es)
TR (1) TR201901422T4 (es)
WO (2) WO2016055537A1 (es)
ZA (2) ZA201702209B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
EP3006453A1 (en) 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
WO2018183947A1 (en) 2017-03-31 2018-10-04 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
CN117281790A (zh) 2018-12-19 2023-12-26 科塞普特治疗公司 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CN110698527B (zh) * 2019-11-19 2022-08-26 湖南新合新生物医药有限公司 一种高纯度氢化可的松-17-戊酸酯的制备方法
CN112028956A (zh) * 2020-09-10 2020-12-04 那路新 合成21-羟基-17-(1-氧代丙氧基)孕甾-4-烯-3,20-二酮的方法
CN114113603B (zh) * 2021-06-30 2023-11-17 四川大学华西医院 Cytl1作为胃癌预后标志物的应用
CN116135871A (zh) * 2021-11-16 2023-05-19 石家庄迪斯凯威医药科技有限公司 一种具有抗耐药性的抗菌化合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1195748B (de) * 1961-06-24 1965-07-01 Vismara Francesco Spa Verfahren zur Herstellung von 1'-substituierten 17alpha, 21-(1'-Alkoxy)-methylendioxysterioden
BE619180A (fr) * 1961-06-24 1962-12-20 Vismara Francesco Spa 17-monoesters de 17 alpha, 21-dihydroxy stéroïdes et leur procédé de préparation
NL6605514A (es) * 1966-04-25 1967-10-26
DE2748442C3 (de) 1977-10-26 1981-08-27 Schering Ag Berlin Und Bergkamen, 1000 Berlin 17α-(3-Jodbenzoyloxy)-9α -chlor4-pregnen-3.20-dione, Zwischenprodukte und Verfahren zu ihrer Herstellung, 9α -chlor-17α, 21-dihydroxy-1,4-pregnadien-3,20-dion und dieses enthaltende Arzneimittel
EP0001737B1 (de) 1977-10-26 1981-01-07 Schering Aktiengesellschaft 17-Alpha-(3-Jodbenzoyloxy)-9-Alpha-chlor-4-pregnen-3.20-dione, deren D-Homo-analoga und Verfahren zu ihrer Herstellung
ATE12237T1 (de) * 1980-12-23 1985-04-15 Schering Ag Neue 6-alpha-methylhydrocortison-derivate, ihre herstellung und verwendung.
ATE8790T1 (de) 1981-02-02 1984-08-15 Schering Corporation Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
US4920216A (en) * 1987-05-28 1990-04-24 The Trustees Of Columbia In The City Of New York Selective chlorination of steroids and other substrates directed by covalently linked pyridine derivatives acting as templates
US5990099A (en) 1988-10-31 1999-11-23 Alcon Laboratories, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
DE69014103T2 (de) 1989-02-07 1995-05-18 Upjohn Co Enthalogenierung organischer verbindungen unter verwendung von zinn oder blei.
DE4121484A1 (de) 1991-06-26 1993-01-07 Schering Ag Verfahren zur herstellung von 6-methylensteroiden
US6172054B1 (en) 1995-06-15 2001-01-09 Alcon Laboratories, Inc. Combination therapy for lowering and controlling intraocular pressure
WO2000049993A2 (en) 1999-02-24 2000-08-31 Nitromed, Inc. Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
ATE251449T1 (de) 1999-06-14 2003-10-15 Cosmo Spa Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
IT1314184B1 (it) 1999-08-12 2002-12-06 Nicox Sa Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
AU2001217709B2 (en) 2000-11-16 2005-10-13 Alcon Manufacturing, Ltd. Combination therapy for lowering and controlling intraocular pressure
ITMI20011762A1 (it) * 2001-08-10 2003-02-10 Cosmo Spa Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione
ITMI20051695A1 (it) 2005-09-14 2007-03-15 Cosmo Spa Uso di 17a-esteri c3-c10 del 9,11-deidrocortexolone cme agenti anti-gonadotropinici
DE102006059063A1 (de) 2005-12-24 2007-06-28 Bayer Healthcare Ag Verwendung von BAY 59-3074 zur Herstellung von Medikamenten zur Therapie von Hirntumoren sowie Kombinationen von BAY 59-3074
US7687484B2 (en) 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
ITMI20071616A1 (it) 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
CN101397317A (zh) 2007-09-27 2009-04-01 天津药业研究院有限公司 一种新型硝酸酯类甾体化合物
WO2009076170A2 (en) * 2007-12-13 2009-06-18 Novartis Ag Combinations of therapeutic agents for treating cancer
JP2010515777A (ja) 2008-03-18 2010-05-13 シコール インコーポレイティド 空気感受性ステロイドの精製
JP5930412B2 (ja) * 2010-06-01 2016-06-08 メタノミクス ヘルス ゲーエムベーハー 対象において膵臓がんを診断する手段及び方法
US20120245552A1 (en) 2011-03-23 2012-09-27 Pop Test Cortisol Llc Combination Therapy
RU2506974C1 (ru) 2012-11-06 2014-02-20 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения первично нерезектабельного рака легкого
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
EP3006453A1 (en) * 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors

Also Published As

Publication number Publication date
IL272095B (en) 2022-12-01
IL272095A (en) 2020-03-31
CN107074905A (zh) 2017-08-18
US10646497B2 (en) 2020-05-12
SI3456330T1 (sl) 2021-09-30
CN107074905B (zh) 2019-08-09
DK3456330T3 (da) 2021-07-26
JP6735739B2 (ja) 2020-08-05
KR102520411B1 (ko) 2023-04-11
CN107001406B (zh) 2020-03-27
CN111285913A (zh) 2020-06-16
AU2020201446B2 (en) 2021-03-18
US10993949B2 (en) 2021-05-04
US20170360806A1 (en) 2017-12-21
JP2017530184A (ja) 2017-10-12
MX2017004661A (es) 2017-10-16
HUE041503T2 (hu) 2019-05-28
RU2020102939A (ru) 2020-05-20
US20170304318A1 (en) 2017-10-26
JP6503057B2 (ja) 2019-04-17
PL3204400T3 (pl) 2019-05-31
TR201901422T4 (tr) 2019-02-21
WO2016055533A1 (en) 2016-04-14
ES2713699T3 (es) 2019-05-23
US20190175618A1 (en) 2019-06-13
KR20230052990A (ko) 2023-04-20
EP3204012B1 (en) 2020-06-03
US20230128438A1 (en) 2023-04-27
RS58607B1 (sr) 2019-05-31
US10231980B2 (en) 2019-03-19
MX2017004660A (es) 2017-10-16
KR20170063821A (ko) 2017-06-08
RU2017115773A (ru) 2018-11-15
CN107001406A (zh) 2017-08-01
DK3204400T3 (en) 2019-03-04
CA3160391A1 (en) 2016-04-14
JP7028809B2 (ja) 2022-03-02
JP2021046418A (ja) 2021-03-25
RU2017115773A3 (es) 2019-03-15
HRP20211177T1 (hr) 2021-10-29
JP2020143140A (ja) 2020-09-10
RU2017115771A3 (es) 2019-03-11
KR20210012047A (ko) 2021-02-02
IL251028A0 (en) 2017-04-30
PT3204400T (pt) 2019-02-25
EP3456330A1 (en) 2019-03-20
AU2015330003A1 (en) 2017-04-13
CA2962746A1 (en) 2016-04-14
AU2020201446A1 (en) 2020-05-14
KR20170063799A (ko) 2017-06-08
SI3204400T1 (sl) 2019-04-30
BR112017007076B1 (pt) 2023-12-19
LT3204400T (lt) 2019-04-10
IL272095B2 (en) 2023-04-01
EP3006453A1 (en) 2016-04-13
ES2806094T3 (es) 2021-02-16
LT3456330T (lt) 2021-08-10
US10183030B2 (en) 2019-01-22
BR112017007078A2 (pt) 2017-12-26
RS62147B1 (sr) 2021-08-31
EP3204400B1 (en) 2018-12-12
RU2712950C2 (ru) 2020-02-03
ZA201702209B (en) 2019-08-28
KR102248983B1 (ko) 2021-05-10
RU2712752C2 (ru) 2020-01-31
ES2882223T3 (es) 2021-12-01
RU2017115771A (ru) 2018-11-12
CA2960928A1 (en) 2016-04-14
EP3456330B1 (en) 2021-05-19
US11986484B2 (en) 2024-05-21
AU2015329999B2 (en) 2020-01-23
HRP20190194T1 (hr) 2019-04-19
EP3204012A1 (en) 2017-08-16
AU2015329999A1 (en) 2017-04-06
EP3204400A1 (en) 2017-08-16
US20210299145A1 (en) 2021-09-30
BR112017007076A2 (pt) 2017-12-26
JP2019070033A (ja) 2019-05-09
WO2016055537A1 (en) 2016-04-14
CN111285913B (zh) 2023-01-10
CN115671114A (zh) 2023-02-03
PL3456330T3 (pl) 2021-11-15
US11712443B2 (en) 2023-08-01
MX366294B (es) 2019-07-04
IL251028B (en) 2020-01-30
PT3456330T (pt) 2021-07-13
IL251371A0 (en) 2017-05-29
US20190091240A1 (en) 2019-03-28
ZA201902320B (en) 2022-11-30
JP2017530171A (ja) 2017-10-12
CN116102604A (zh) 2023-05-12
HUE055143T2 (hu) 2021-11-29
US20200215080A1 (en) 2020-07-09
CA2960928C (en) 2023-10-31

Similar Documents

Publication Publication Date Title
MX2019008063A (es) 17a, 21-diesteres de cortexolona para uso en el tratamiento de tumores.
PH12018500284A1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
TW201613901A (en) New compounds
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
GB201209613D0 (en) New compounds
MY189427A (en) Pyrazolyl quinoxaline kinase inhibitors
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
IN2014MN00986A (es)
MX366899B (es) Nuevos compuestos.
GB201118656D0 (en) New compounds
MX369803B (es) Derivados de acilaminopirimidina para el tratamiento de infecciones viricas y otras enfermedades.
MD4643C1 (ro) Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin
MX2018003563A (es) Nuevos compuestos.
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
MX2020000135A (es) Nuevos compuestos de quinolinona.
MX2018001751A (es) Dihidroquinolinonas aril-sustituidas, su preparacion y su uso como farmaceuticos.
MX2017009608A (es) Compuestos anticancerigenos.
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
MX2018003564A (es) 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer.
AU2017260751A1 (en) Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine